David Persinger
Family · Columbus, OHNPI 1245615889
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Gilead at 31.8% of the total. 2025 is the largest year on record at $1,206, 2.9 times the $422 reported in 2022. Among family clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $23.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$1K
- Viiv Healthcare Company$979
- Merck$185
- Johnson & Johnson$146
- AbbVie$122
- Lilly USA, LLC$117
- plus $800 from 19 others
What the payments were for
- Travel & lodging$110%
- Food & beverage$3,433100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 42 | $1,094 |
| Viiv Healthcare Company | 40 | $979 |
| Merck | 9 | $185 |
| Johnson & Johnson | 9 | $146 |
| AbbVie | 7 | $122 |
| Lilly USA, LLC | 6 | $117 |
| Boehringer Ingelheim | 1 | $109 |
| Exact Sciences | 4 | $85 |
| Napo Pharmaceuticals Inc | 3 | $75 |
| Theratechnologies Inc. | 3 | $60 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| Verity Pharmaceuticals Inc. | 2 | $58 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $50 |
| EMD Serono, Inc. | 2 | $48 |
| Novo Nordisk | 3 | $44 |
| Organon | 1 | $35 |
| Pfizer | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Vertex | 1 | $21 |
| Lundbeck LLC | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Coopersurgical, Inc. | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Antares Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,444 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 87 | $339,548 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 25 | $109,010 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 28 | $105,419 |
| DescovyEmtricitabine/Tenofov Alafenam | 44 | $102,965 |
| DovatoDolutegravir Sodium/Lamivudine | 35 | $98,380 |
| TivicayDolutegravir Sodium | 38 | $80,827 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 20 | $77,091 |
| JulucaDolutegravir/Rilpivirine | 13 | $45,897 |
| PrezcobixDarunavir/Cobicistat | 20 | $45,315 |
| TrulicityDulaglutide | 32 | $29,165 |
| JardianceEmpagliflozin | 40 | $28,017 |
| Spiriva RespimatTiotropium Bromide | 28 | $14,695 |
| FarxigaDapagliflozin Propanediol | 15 | $12,538 |
| Testosterone | 24 | $8,923 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $6,674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $1,094 | $547,932159 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Triumeq, Juluca | $979 | $302,195106 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Synjardy Xr | $109 | $49,38580 claims |
| Johnson & JohnsonPrezcobix | $146 | $45,31520 claims |
| Lilly USA, LLCTrulicity | $117 | $29,16532 claims |
| AstraZenecaFarxiga | $17 | $12,53815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.
Other family in Columbus
- Christina GastColumbus$66K
- Beth LoessinColumbus$34K
- Mary HurleyColumbus$15K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.